Van ECK Associates Corp Invests $3.42 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Van ECK Associates Corp purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 199,630 shares of the biotechnology company’s stock, valued at approximately $3,424,000. Van ECK Associates Corp owned 0.08% of ADMA Biologics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Vontobel Holding Ltd. raised its stake in shares of ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 888 shares during the period. GAMMA Investing LLC increased its holdings in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares in the last quarter. State of Alaska Department of Revenue raised its position in ADMA Biologics by 1.0% in the fourth quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company’s stock valued at $2,304,000 after purchasing an additional 1,337 shares during the period. Hollencrest Capital Management purchased a new position in ADMA Biologics in the third quarter valued at about $30,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of ADMA Biologics by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 1,509 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Down 0.6 %

Shares of NASDAQ ADMA opened at $16.07 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64. The stock’s 50-day simple moving average is $17.08 and its 200-day simple moving average is $17.89. The firm has a market cap of $3.80 billion, a price-to-earnings ratio of 57.38 and a beta of 0.75.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of recent research reports. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.70% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.